pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973.

9. The combination of any one of claims 1-7, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with PD-0325901.

10. The combination of any one of claims 1-9, wherein the compound of formula I or the salt thereof is to be administered simultaneously with the one or more agents.

11. The combination of any one of claims 1-9, wherein the compound of formula I or the salt and the one or more agents are to be administered sequentially.

12. The combination of any one of claims 1-9, wherein administration of the one or more agents begins about 1 to about 10 days before administration of the combination.

13. The combination of any one of claims 1-9, wherein administration of the compound of formula I or the salt thereof begins about 1 to about 10 days before administration of the combination.

14. The combination of any one of claims 1-9, wherein administration of the compound of formula I or the salt thereof and administration of the one or more agents begins on the same day.

15. The combination of any one of claims 1-7, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973, and the cancer is pancreatic.

16. The combination of any one of claims 1-7, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973, and the cancer is non-small cell lung cancer.

17. The combination of any one of claims 1-7, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973, and the cancer is breast.

18. The combination of any one of claims 1-7, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973, and the cancer is colon.

19. The combination of any one of claims 1-7, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973, and the cancer is melanoma.

20. A compound of formula I or a pharmaceutically acceptable salt thereof, for therapeutic use for improving the quality of life of a patient treated for a hyperproliferative disorder with an agent selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof.

21. The combination of a) a compound of formula I or a pharmaceutically acceptable salt thereof; and b) one or more agents selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof for treating a hyperproliferative disorder.

22. The combination of a) a compound of formula I or a pharmaceutically acceptable salt thereof; and b) one or more agents selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof for treating a disease or condition modulated by AKT kinase.

23. The use of the combination of a compound of formula I or a pharmaceutically acceptable salt thereof and GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of a hyperproliferative disorder in a mammal.

24. The use of the combination of a compound of formula I or a pharmaceutically acceptable salt thereof and GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof in preparation of a medicament for the treatment of a disease or condition modulated by AKT kinase in a mammal.

25. A kit comprising a compound of formula I or a pharmaceutically acceptable salt thereof, a container, and a package insert or label indicating the administration of the

compound of formula I with one or more agents selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof for treating a hyperproliferative disorder.

26. A product comprising a compound having formula I or a pharmaceutically acceptable salt thereof, and one or more agents selected GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof; as a combined preparation for separate, simultaneous or sequential use in the treatment of a hyperproliferative disorder.

27. ~~A method for treating a hyperproliferative disorder in a mammal, comprising administering to the mammal~~ Use of a combination of a compound of formula I:



(I)

or a pharmaceutically acceptable salt thereof; and another agent selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a hyperproliferative disorder in a mammal.

28. ~~A method for treating a disease or condition modulated by AKT kinase in a mammal comprising, administering to the mammal,~~ Use of a) a compound of formula I or a pharmaceutically acceptable salt thereof; and b) one or more agents selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition modulated by AKT kinase in a mammal.